Tu Youyou's team: New breakthrough in research on 'artemisinin resistance'
After years of hard work, Tu Youyou and her team have made new breakthroughs in the areas of "anti-malarial mechanism research", "causes of drug resistance" and "adjustment of treatment methods", and recently proposed practical treatment solutions to deal with the problem of "artemisinin resistance", and made new progress in "artemisinin treatment for lupus erythematosus and other indications" and "the export of traditional Chinese medicine scientific research papers", which have been highly recognized by the World Health Organization and authoritative experts at home and abroad.
Professor Cox, editor-in-chief of the Oxford Textbook of Medicine, said he was pleased with the upcoming inclusion of traditional Chinese medicine treatises in the textbook. He said: "The chapter on Chinese medicine is both important and in-depth. It is all the result of the outstanding efforts of Chinese scientists." Pedro Alonso and other leading experts believe that Tu Youyou's team has built a bridge between traditional medicine and modern medicine, allowing Chinese medicine to be not only widely used in China, but also recognized in more and more countries for its effective treatment. We hope Chinese scientists will continue to make more noise in the international arena of artemisinin research.
Looking for chemical products? Let suppliers reach out to you!
Chinese Medicine Innovation Development
2026-06-06
-
Life Science Ingredients Industry Overview
This issue offers a deep exploration of the evolving pharmaceutical and nutrition landscape, combining data, analysis, and insight to reveal key industry shifts and emerging directions. Support online permanent download.Published in: Nov. 2025
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
The relationship between Digital Transformation and Work- Life Balance in the Egyptian Pharmaceutical Industry
-
What Does the Future Hold for the Anti-Obesity Drug Market in 2024?
-
Hengrui entered the top 20 for the first time. How big is the gap between Chinese and American pharmaceutical companies?
-
The State Food and Drug Administration accepted the marketing application of Ditze Pharma suvortinib
-
Jimin's innovative polycystic kidney disease innovative drug was approved by the FDA for clinical trials
-
Another giant may be broken up
-
NASH is on the verge of a new drug, and the 40-year black hole is finally shining a light
-
Novo Nordisk Shanghai and ShanghaiPharmaceutical Holdings sign a contract to make another breakthrough incooperation
-
Zebutinib recommended as 'Class I priority' in international guidelines
-
FDA approves 'ibrutinib' for chronic graft-versus-host disease in children 1 year and older
Recommend Reading
-
Torrent Pharma Targets First Wave Semaglutide Launch Revenue Up 11 Percent as Patent Ends
-
FDA Clears Sanofi’s Wayrilz (rilzabrutinib) for Adult ITP; U.S. Launch in September
-
AstraZeneca Targets Year-End Filing for Novel Hypertension Drug Baxdrostat
-
Aficamten Beats Metoprolol in Obstructive HCM, Strengthening Case Ahead of FDA Decision
-
FDA Names Veteran Oncology Regulator Pazdur as Director of Drug Review Center
-
Mitsubishi Chemical Exits the Manufacturing of Polyester Resins for Printer Toners
-
Continental Tires Out, Franchise Power In: Continental Group Spins Off French Retail Arm to ASC in Strategic Pivot
-
L'Oréal Acquires Professional Hair Care Brand Color Wow
-
Guangdong Jieyang Puts into Operation the World's First "One-Step" Waste Plastic Recycling Plant, Processing 200,000 Tons of Mixed Plastics Annually
-
C&EN 2025 Global Top 50 BASF Leads with $70.6B Sales 11 Chinese Firms Make the List